Cimzia® (certolizumab pegol)
remission at a reduced
maintenance dose in
severe active axSpA.2
The first anti-TNF with a licensed indication for
reduced maintenance dosing in severe active axSpA.1-8
Due to the emerging biosimilar market, trusts are being encouraged to use the best value biologic as the first line option.9 In addition to financial costs, it is important to consider the wider impact on the patient, their family and the NHS when a patient is on a treatment journey e.g. switching treatments, repeated hospital visits, loss of work days.10
Help us to grow our resource the way you want it to grow.